Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Osteoporosis, Post-menopausal Clinical Trial

Official title:
Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate how teriparatide or zoledronic acid affects the bone of postmenopausal osteoporotic women after 6 months of treatment as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis). After completing 12 months of treatment all participants are eligible to participate in an additional 12-month open label extension.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00927186
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 4
Start date	July 2009
Completion date	April 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00532207` - Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis	Phase 3
Completed	`NCT00018447` - Combination Osteogenic Therapy in Established Osteoporosis	Phase 2
Completed	`NCT00532246` - Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo	Phase 4
Completed	`NCT00543023` - A Study of the Treatment of Postmenopausal Women With Osteoporosis	Phase 3
Completed	`NCT00543218` - PTH Comparison in Post Menopausal Women	Phase 3
Completed	`NCT00532428` - Long Term Effects of Raloxifene Treatment on Bone Quality	Phase 4
Completed	`NCT00532545` - Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis	Phase 4